Insulin Under the BPCIA: Opportunities and Obstacles

On November 10, Axinn partner Bradley Justus will speak on the "Balancing Cost & Counsel: Optimizing Legal Budgets" roundtable discussion at ALM General Counsel Conference East, being held November 10-11 in New York. 

Axinn is pleased to announce that it is acting as regulatory counsel to Thermo Fisher Scientific Inc. (“Thermo Fisher”) in its recently announced definitive agreement to acquire Clario Holdings, Inc. (“Clario”), a global leader in clinical-trial endpoint data solutions, from a shareholder group led by Astorg and Nordic Capital, Novo Holdings, and Cinven. The transaction, valued at approximately $9 billion in cash at closing, plus potential additional performance-based payments, underscores Thermo Fisher’s strategy to deepen its digital, data, and artificial intelligence capabilities in clinical research and biopharma services markets. Following the close, Clario will become part of Thermo Fisher’s Laboratory Products & Biopharma Services segment.